- Home
- MTA vs MNPR Comparison
MTA vs MNPR Comparison
Compare MTA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTA
- MNPR
- Stock Information
- Founded
- MTA 1983
- MNPR 2014
- Country
- MTA Canada
- MNPR United States
- Employees
- MTA N/A
- MNPR N/A
- Industry
- MTA
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MTA
- MNPR Health Care
- Exchange
- MTA Nasdaq
- MNPR Nasdaq
- Market Cap
- MTA 641.3M
- MNPR 531.6M
- IPO Year
- MTA N/A
- MNPR 2019
- Fundamental
- Price
- MTA $6.36
- MNPR $82.50
- Analyst Decision
- MTA Hold
- MNPR Strong Buy
- Analyst Count
- MTA 1
- MNPR 12
- Target Price
- MTA $7.50
- MNPR $96.64
- AVG Volume (30 Days)
- MTA 882.4K
- MNPR 102.1K
- Earning Date
- MTA 11-14-2025
- MNPR 11-10-2025
- Dividend Yield
- MTA N/A
- MNPR N/A
- EPS Growth
- MTA N/A
- MNPR N/A
- EPS
- MTA N/A
- MNPR N/A
- Revenue
- MTA $8,167,999.00
- MNPR N/A
- Revenue This Year
- MTA $117.14
- MNPR N/A
- Revenue Next Year
- MTA $69.62
- MNPR N/A
- P/E Ratio
- MTA N/A
- MNPR N/A
- Revenue Growth
- MTA 70.70
- MNPR N/A
- 52 Week Low
- MTA $2.45
- MNPR $14.88
- 52 Week High
- MTA $7.73
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- MTA 44.53
- MNPR 52.39
- Support Level
- MTA $6.24
- MNPR $77.00
- Resistance Level
- MTA $6.97
- MNPR $86.14
- Average True Range (ATR)
- MTA 0.34
- MNPR 6.00
- MACD
- MTA -0.14
- MNPR -1.21
- Stochastic Oscillator
- MTA 11.26
- MNPR 60.62
About MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.